Springer Nature
Browse
12967_2017_1197_MOESM9_ESM.pptx (93.99 kB)

MOESM9 of Transcriptomic profiling and quantitative high-throughput (qHTS) drug screening of CDH1 deficient hereditary diffuse gastric cancer (HDGC) cells identify treatment leads for familial gastric cancer

Download (93.99 kB)
presentation
posted on 2017-05-01, 05:00 authored by Ina Chen, Lesley Mathews-Greiner, Dandan Li, Abisola Abisoye-Ogunniyan, Satyajit Ray, Yansong Bian, Vivek Shukla, Xiaohu Zhang, Raj Guha, Craig Thomas, Berkley Gryder, Athina Zacharia, Joal Beane, Sarangan Ravichandran, Marc Ferrer, Udo Rudloff
Additional file 9: Figure S7. Increased induced cell death upon treatment with topoisomerase II and dual PI3K/mTOR in hereditary c.1380delA CDH1 SB.mhdgc-1 versus sporadic gastric cancer cell lines. Caspase 3/7 levels after 24 h of treatment with 1 µM mitoxantrone, 1 µM etoposide, or 1 µM PI-103 normalized to DMSO-treated control is shown (standard errors of the mean from at least 2 independent experiments done in triplicate shown).

Funding

National Institutes of Health

History

Usage metrics

    Journal of Translational Medicine

    Categories

    Keywords

    Hereditary diffuse gastric cancer (HDGC)High throughput drug screeningTherapeutic leadsc.1380delA CDH1 gastric cancer cellsDifferential gene expression profiling

    Licence

    CC BY + CC0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC